

Special Issue

Stem Cell Transplant and Cellular Therapies on Multiple Myeloma

Message from the Guest Editor

Stem cell transplant remains a cornerstone in multiple myeloma treatment. Cellular therapies are emerging as promising treatments in the relapsed and refractory setting and may even challenge frontline treatment options. The use of a patient's own stem cells or immune cells is key to obtaining long-lasting remission in different parts of the multiple myeloma treatment journey. The use of genetically modified T or NK cells from the patient or from healthy donors has also shown dramatic activity in the relapse and refractory setting. Autologous CAR-T cells directed against the B cell maturation antigen (BCMA) have been marketed after the outstanding results of recent phase 2 trials. Furthermore, phase 3 results support the use of CAR-T cells in earlier lines. CAR-T therapy is likely to challenge consolidation and maintenance strategies or even autologous stem cell transplantation in the near future. In this Special Issue, original reviews and articles that focus on the current use of stem cell transplant and cellular therapies on multiple myeloma are welcome.

Guest Editor

Dr. Albert Oriol

Institut Josep Carreras and Institut Català d'Oncologia, Hospital Germans Trias i Pujol, 08916 Badalona, Spain

Deadline for manuscript submissions

closed (31 August 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/172815

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)